This essay shows the roles to engage to combat this never-ending concern.

Pharmaceutical statistical organizations have become so focused on regulatory process that they've lost the ability to actually analyze data, and it's setting up failures no one sees coming.

Imagine Billie Bob Thornton portraying a biotech CEO—now imagine learning about drug development risk along the way.

This essay argues that introductory statistics should prioritize numerical literacy and interpretation over mathematical and computational procedures.

Read with last week’s post.

When we have time to think, mathematics can clarify choices that instinct alone cannot resolve.

The history of creatinine clearance shows that scientific progress comes less from refining formulas than from improving the biological quantities they are meant to estimate. A model is useful for conveniently estimating the underlying biology.

Its luck was revealed in childhood; its power lies in knowing where unequal allocation helps, and where it cannot.

This blog shows how to reason quantitatively about FDA’s proposed policy change instead of defaulting to either alarm or celebration.

From crime fiction to sufficient statistics, why every layer of modeling necessarily blurs information rather than creating it.

What a few college football games reveal about weighing evidence, applying models, and making informed decisions — lessons that extend far beyond the field.

Statistics did not disappear; one of its creations has become powerful, and with that power comes responsibility we are currently failing to take seriously.

A guide to avoiding wasted potential in clinical trials by leveraging repeated measures and integrating pharmacology and biological insights into analysis.

Thanksgiving stories lead to a broader lesson: knowing all possibilities allows one to apply six critical levers for smarter study design.

Being a technically great statistician is not enough: before your skills can shine, you must open the door that allows you to establish credibility with each scientist you work with and then establish it.

This blog offers a framework for making responsible Proof-of-Concept decisions when budgets limit sample size, showing how adaptive thinking replaces rigid historical dogma.

A dog may follow commands without understanding why, but in science, blindly following ‘statistical’ rules without grasping the principles can lead to cherry picking, misinterpretation, and compromised integrity.

When diagnostic observations are presented as facts, the consequences ripple through public perception, funding, and the progress of science itself.

In last week's blog, I showed that the Frequentist/Bayesian divide is largely philosophical, with practical differences between approaches being limited. Even unique Bayesian methods can often be interpreted in a frequentist manner. Yet, adoption of these methods, dubbed Bayesian, even when appropriately applied, has been slow in drug development. This article explains why.

Despite the tribal divide, Bayesian and Frequentist methods produce nearly the same action in the preponderance of situations.